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From birth to adulthood, the gutmicrobiota matures from a simple
community dominated by a few major
bacterial groups into a highly diverse eco-
system that provides both benefits and
challenges to the host. Currently there is
great interest in identifying environmen-
tal and host factors that shape the devel-
opment of our gut microbiota. Breast
milk is a rich source of maternal antibod-
ies, which provide the first source of
adaptive immunity in the newborn’s
intestinal tract. In this addendum, we
summarize our recent data demonstrat-
ing that maternal antibodies in breast
milk promote long-term intestinal
homeostasis in suckling mice by regulat-
ing the gut microbiota and host gene
expression. We also discuss important
unanswered questions, future directions
for research in this field, and implications
for human health and disease.
Introduction
As children we are often told, “Listen
to your mother!” and (usually much later)
we appreciate the wisdom of her advice. It
turns out that in addition to regulating
our behavior, our mothers play a key role
in regulating our gut microbiota and our
own responses to that diverse microbial
community. During parturition, our pre-
viously sterile gastrointestinal tracts receive
their first inoculation with microbes from
our mothers. Interestingly, the composi-
tion of our initial gut microbiota is influ-
enced substantially by the mode of
delivery. A recent study of mothers and
newborns revealed that the early micro-
biota of vaginally delivered infants resem-
bled their mother’s vaginal microbiota,
whereas the microbiota of infants deliv-
ered by Caesarian section was more simi-
lar to that found on the skin surface.1
Over time, our gut microbiota matures
from a simple community dominated by a
few major bacterial groups into a highly
diverse adult microbiota (for a review, see
ref. 2). The development of our gut
microbiota is regulated by environmental
factors, including diet, and by host factors
associated with innate and adaptive
immunity. There is a growing body of epi-
demiological evidence that the composi-
tion of the gut microbiota differs
significantly between breast-fed and for-
mula-fed infants.3-10 For breastfed infants,
maternal antibodies provide the first
source of antigen-specific immunity in the
intestinal tract (for a review see ref. 11).
The predominant type of antibody in
breast milk is secretory (S)IgA, which is
transported across mammary gland epi-
thelial cells by the polymeric immuno-
globulin receptor (pIgR).12 At the apical
surface, proteolytic cleavage releases SIgA,
in which IgA is covalently attached to
secretory component (SC), the extracellu-
lar domain of pIgR. The SC moiety of
SIgA protects SIgA from degradation by
host and microbial proteases and provides
additional innate immune functions. The
mucosal epithelial chemokine CCL28 is
up-regulated in the mammary gland dur-
ing lactation, and plays a key role in
attracting IgACCCR10C antibody-secret-
ing cells that were primed in mucosal lym-
phoid tissues of the intestinal and
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respiratory tracts.13 Thus, a significant
proportion of the SIgA antibodies in
breast milk are targeted against microbes
in the mother’s gastrointestinal tract,
which are the same microbes that will seed
the gut microbiota of the infant (for a
review see ref. 14). However, the specific
mechanisms through which breast milk-
derived SIgA may regulate the gut micro-
biota of suckling infants have not system-
atically been investigated. Furthermore,
little is known about the long-term effects
of breastfeeding on the composition of the
microbiota of older children and adults.
Our recently published work15 employed
a mouse model to investigate the role of
maternal SIgA on short- and long-term
regulation of the gut microbiota.
Breast Milk-Derived SIgA vs.
Endogenous SIgA
Breast milk contains many bioactive
molecules, including SIgA, which could
potentially regulate the composition of
the gut microbiota and the host response
to these microbes.16,17 As the intestinal
immune system develops in the offspring,
there is a slow transition to endogenous
production of SIgA via pIgR-mediated
transport of locally synthesized IgA into
the gut lumen. In human infants the tim-
ing of endogenous SIgA production varies
widely, influenced by environmental fac-
tors such as microbial load in the intes-
tine.18 Whereas endogenous production
of SIgA has been demonstrated in infants
in developing countries, it may take sev-
eral years before the concentrations of
intestinal SIgA achieve adult levels in
developed countries where exposure to
environmental and dietary microbes is
lower. To develop a mouse model in
which we could separate the effects of
breast milk-derived and endogenous SIgA,
while holding other factors in breast milk
constant, we utilized mice with a targeted
deletion in the Pigr gene (Fig. 1). Pigr¡/¡
mice cannot transport SIgA into external
secretions, including milk and intestinal
fluids.19 By breeding PigrC/¡ females with
Pigr¡/¡ males, and vice versa, we gener-
ated offspring that were or were not
exposed to maternal SIgA in breast milk.
The genotypes of the offspring of both
crosses were equally distributed between
PigrC/¡ and Pigr¡/¡, the former of which
could produce endogenous SIgA by trans-
port across intestinal epithelial cells, and
the latter of which could not. Surprisingly,
we found high levels of IgA in the milk
from both PigrC/¡ and Pigr¡/¡ dams, sug-
gesting that IgA could enter the milk
stream by paracellular leakage in the
absence of pIgR-mediated transport.
While this SC-devoid IgA was found in
the stomachs of suckling newborns, it did
not survive transport through the prote-
ase-rich environment of the intestinal
tract. We found that the colonic lumens
of newborn offspring of Pigr¡/¡ dams
were totally devoid of IgA, whereas the
offspring of PigrC/¡ mice had abundant
IgA in their colonic lumens and in their
feces. At weaning, fecal IgA levels dropped
to low levels in all mice, reflecting the loss
of maternal SIgA. Fecal IgA levels began
to increase at about 4 weeks of age in
PigrC/¡ offspring, regardless of maternal
Pigr genotype, reflecting endogenous
pIgR-mediated transport of IgA across
intestinal epithelial cells. By contrast, fecal
IgA was undetectable in Pigr¡/¡ offspring
for the rest of their lives. Thus our model
system allowed us to study 4 distinct
groups of mice that differed only in the
presence of maternal and/or endogenous
SIgA.
Breast Milk-Derived SIgA
Strengthens the Intestinal Barrier
Epidemiological studies have provided
support for the concept that SIgA
antibodies in breast milk provide protec-
tion against a wide range of bacterial, viral
and parasitic infections in suckling infants
(for a review, see ref. 11). There is also evi-
dence that early exposure to breast milk-
derived SIgA may reduce the incidence of
allergic diseases later in life. However, the
benefits of breast milk-derived SIgA
remain controversial, largely due to the
lack of standardization of epidemiological
studies with regard to duration of breast-
feeding, concentrations of SIgA and other
anti-inflammatory factors in breast milk,
and effects of other variables such as diet
and sanitation. While the predominant
protective mechanism of SIgA in breast
milk likely involves immune exclusion of
pathogens and allergens at mucosal surfa-
ces of the suckling infant, other protective
mechanisms could include innate
enhancement of the intestinal barrier and
promotion of a healthy commensal micro-
biota that limits the growth of potential
pathogens. We hypothesized that early
exposure to maternal SIgA antibodies in
breast milk would foster a mutualistic
relationship with the developing micro-
biota, and could enhance intestinal barrier
function. In our mouse model, we found
that failure to receive SIgA in breast milk
resulted in increased translocation of
aerobic bacteria from the neonatal gut
into draining mesenteric lymph nodes,
regardless of the Pigr genotype of the off-
spring. A prominent species among the
bacteria that breached the epithelial bar-
rier was Ochrobactrum anthropi, which has
been identified as an opportunistic patho-
gen in preterm infants and immunocom-
promised individuals.20-22 Although
Figure 1. Breeding scheme for generating offspring mice exposed to breast milk-derived maternal
SIgA and/or endogenous SIgA derived from intestinal epithelial transport of locally synthesized IgA.
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significant numbers of bacteria were able
to penetrate the intestinal barrier in the
absence of breast milk-derived SIgA, there
was no evidence of systemic infection.
This finding was not surprising, given that
the systemic immune systems of the neo-
natal mice were intact. However, it should
be noted that our mice were maintained
under specific pathogen-free conditions,
housed in barrier cages with sterile bed-
ding, and fed autoclaved food and water.
Future experiments in which mice
deprived of maternal SIgA are challenged
with known pathogens could shed light
on the protective effects of SIgA antibod-
ies in breast milk. It will be particularly
interesting to compare responses to patho-
gen challenges in the early post-weaning
period vs. later in life.
SIgA Antibodies in Breast Milk
Regulate the Commensal Gut
Microbiota
There is substantial evidence from
studies in humans and mice that intestinal
SIgA regulates the composition and activ-
ity of the commensal microbiota (for a
review, see ref. 11). Less well understood
are the effects of breast milk-derived SIgA
on the developing gut microbiota, and
whether these effects persist into later life.
To analyze the short- and long-term
effects of maternal SIgA, while controlling
for endogenous SIgA, we analyzed the
composition of the fecal microbiota in
PigrC/¡ offspring of PigrC/¡ and Pigr¡/¡
dams at weaning (3 weeks of age), and in
the same mice when they reached adult-
hood (10 weeks of age). Not only did early
exposure to breast milk-derived SIgA
result in a significantly different micro-
biota at weaning, but these differences
were magnified when the mice reached
adulthood. Some bacterial taxa varied in
abundance due to lack of exposure to
maternal SIgA, whereas other taxa were
uniquely present or absent in the gut
microbiota. Gram-negative Proteobacteria
of the family Pasteurellaceae and Gram-
positive Firmicutes of the family Lachno-
spiraceae dominated the taxa that were
upregulated in the absence of passive
SIgA. By contrast, the majority of unique
taxa that were present in mice deprived of
maternal SIgA were members of the fam-
ily Comamonadaceae (phylum Proteobac-
teria). Interestingly, increased abundance
of Pasteurellaceae and Lachnospiraceae
has been observed in the gut microbiota of
pediatric patients with inflammatory
bowel disease (IBD),23 and increased
abundance of Comamonadaceae has been
observed in the gut microbiota of adult
IBD patients with chronic pouchitis.24
Although caution must be exercised when
comparing results from controlled animal
experiments to human diseases, our find-
ings are consistent with the concept that
early exposure to SIgA in breast milk pro-
motes the development of a healthy
microbiota that may provide long-term
protection against inflammatory diseases.
Early Exposure to SIgA in Breast
Milk Affects Intestinal Epithelial
Gene Expression Later in Life
Microbial-host mutualism in the gut is
promoted by extensive cross-talk between
the gut microbiota and epithelial cells at
the luminal interface, largely mediated by
host receptors that recognize microbe
associated-molecular patterns (for a review
see ref. 25). Having observed that early
exposure to breast milk-derived SIgA
caused long-term alterations in the com-
position of the gut microbiota, we
hypothesized that the epithelial cell
response to this distinctive microbiota
would be altered as well. To test this
hypothesis, we analyzed global gene
expression in epithelial cells isolated from
the colons of adult mice in the 4 groups
comprising our model system. We
observed a unique (and presumably opti-
mal) pattern of gene expression in mice
that had received both maternal and
endogenous SIgA, with specific changes
resulting from the loss of either source of
SIgA. When we challenged these mice in
vivo with the epithelial-disrupting agent
dextran sulfate sodium, we observed that
altered patterns of epithelial gene expres-
sion were correlated with increased suscep-
tibility to colonic inflammation. It can be
postulated that signals from the epithe-
lium (including but not limited to SIgA)
regulate the composition and activity of
the microbiota in such a manner as to
discourage mutually destructive inflam-
matory responses. In this regard it was sig-
nificant that some of the genes whose
expression was regulated by SIgA were
murine orthologs of genes that have been
associated with IBD and other inflamma-
tory diseases in humans, including FUT2,
IRF1, PLA2G2A, SLC26A3, VDR and
ZMIZ1. In summary, our recent findings
suggest that host-microbial mutualism is
promoted by a lifelong relationship
between SIgA and gut microbes, begin-
ning at birth with maternal SIgA antibod-
ies provided in breast milk, and
continuing throughout life with endoge-
nous SIgA antibodies provided by pIgR-
mediated transport across intestinal
epithelial cells. A key aspect of this rela-
tionship, which deserves further investiga-
tion, is the specificity and affinity of SIgA
antibodies directed against gut microbes.
Unanswered Questions, Future
Directions for Research, and
Therapeutic Opportunities
While we believe that our recent find-
ings provide compelling support for the
benefits of breast milk-derived SIgA in
promoting lifelong intestinal homeostasis,
there remain many unanswered questions
and exciting directions for future research.
In order for this field to progress, it will be
essential to elucidate the mechanisms
through which SIgA regulates the gut
microbiota and in turn, gene expression
by host cells. Fig. 2 illustrates theoretical
scenarios for the development of neonatal
intestinal immunity in the presence and
absence of breast milk-derived maternal
SIgA. Our findings suggest that maternal
SIgA regulates the composition of the gut
microbiota in suckling infants, and that
some microbes can penetrate the epithelial
barrier in the absence of maternal SIgA.
However, it is not known whether SIgA
associates preferentially with selected
members of the gut microbiota. If so, does
SIgA promote or inhibit the proliferation
of bacteria with which it is associated? We
recently reported that SIgA is concen-
trated with gut microbes in the loose outer
layer of colonic mucus in mice and
humans, whereas the dense inner layer of
colonic mucus, rich in antimicrobial
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peptides, is relatively devoid of both SIgA
and bacteria.26 One could envision mech-
anisms through which coating of the bac-
terial surface with SIgA could facilitate (or
inhibit) the association of bacteria with
colonic mucus, thus promoting (or block-
ing) biofilm formation. Methods for
fluorescence-activated cell sorting of IgA-
bound fecal bacteria have been devel-
oped,27 and this approach could be cou-
pled with deep sequence analysis of the
SIgA-bound and -unbound bacterial
cohorts. Similar approaches could be used
to investigate how bound SIgA affects
gene expression and metabolic activity of
gut microbes. Understanding the transi-
tion from maternal to endogenous SIgA
will require longitudinal studies in experi-
mental animals and humans. A key ques-
tion to be resolved is, how does early
exposure to breast milk-derived SIgA exert
Figure 2. Hypothetical model of the role of breast milk-derived secretory (S)IgA in the development of intestinal immunity. (A) In the presence of mater-
nal SIgA, gut microbes are concentrated in the loose outer layer of colonic mucus (shown here in light blue), while the dense inner layer of mucus (shown
here in darker blue) is relatively devoid of both SIgA and microbes. Microbial products stimulate intestinal epithelial cells and promote a healthy balance
between pro- and anti-inflammatory gene expression. (B) In the absence of maternal SIgA, the composition of the gut microbiota is altered, and some
microbes penetrate the mucus and epithelial barriers to invade draining mesenteric lymph nodes. Intestinal dysbiosis can persist into adult life and result
in imbalanced pro-inflammatory gene expression in intestinal epithelial cells.
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long-term effects on host-microbial mutu-
alism? There are a number of potential
answers, which are not mutually exclusive
and can be addressed with current tech-
nologies. Key among these involves the
role of SIgA in the transition from the
simple gut microbiota of newborn mam-
mals to the complex microbiota of adults.
An interesting, and testable, hypothesis is
that early exposure to breast milk-derived
SIgA shapes the subsequent endogenous
IgA response to gut microbes. SIgA has
been shown to play a role the natural sens-
ing of commensal bacteria by mouse
Peyer’s patch dendritic cells,28 likely
involving both antigen-specific and gly-
can-mediated recognition of microbes by
SIgA. Thus maternal SIgA could “prime”
the neonatal immune system for recogniz-
ing specific types of gut microbes, which
could lead to the generation of microbe-
specific memory IgAC B cells as a lifelong
source of endogenous SIgA. We know
that, once established, the gut microbiota
is resilient in the face of a wide range of
environmental challenges, such as infec-
tions and antibiotics.2 What is the role of
SIgA in this resilience? Perhaps SIgA-
bound microbes are more resistant to per-
turbation and/or SIgA promotes the
recovery of selected microbial communi-
ties. What is the role of host genetics in
SIgA-epithelial-microbial mutualism?
This question could readily be addressed
by crossing pIgR-sufficient and -deficient
mice with mice bearing other genetic
mutations known to impact intestinal
homeostasis. Given the technology to
generate cell type-specific genetic muta-
tions in mice, there are limitless oppor-
tunities to explore the host-microbial
interface. For example, we recently
reported that mice with an intestinal
epithelial-specific deletion of the Myd88
gene, encoding a cytoplasmic receptor
that interacts with microbial pattern rec-
ognition receptors, had reduced expres-
sion of pIgR, impaired transport of
SIgA, an altered composition of the gut
microbiota, and increased susceptibility
to chemically-induced intestinal inflam-
mation.29 Recent advances in genome-
wide studies of polymorphisms in
humans associated with increased risk
for IBD and other inflammatory diseases
should provide many opportunities for
studying the impact of human genetics
on SIgA expression and function.
In conjunction with mechanistic stud-
ies, there are many avenues through which
the potential benefits of SIgA in infec-
tious, allergic and inflammatory diseases
could be explored. The protective role of
SIgA as a constituent of breast milk in
humans needs to be better defined, begin-
ning with epidemiological studies that
link the concentration and activity of
SIgA in breast milk to its beneficial effects.
An example of this approach is the PAS-
TURE project (Protection against Allergy:
STUdy in Rural Environments), a large
prospective birth cohort study conducted
in Austria, Finland, France, Germany and
Switzerland.30 In this study, levels of SIgA
were analyzed in 610 breast milk samples
collected 2 months after delivery. Multi-
variate logistic regression analysis revealed
a significant inverse association between
the total amount of SIgA that was ingested
via breast milk during the first year of life
and the development of atopic dermati-
tis.31 While this type of epidemiological
study represents a step in the right direc-
tion for assessing the potential benefits of
breast milk-derived SIgA, many questions
remain to be answered. It will be impor-
tant to assess the relationship between
early exposure to SIgA and subsequent
allergic (and inflammatory) diseases in
other geographic settings (including urban
areas) and in other demographic groups.
Approaches could be developed to
improve the quantity and quality of SIgA
in breast milk, for example, nutritional
supplementation and vaccination of preg-
nant women. These studies should be cou-
pled with analyses of the gut microbiota at
birth and throughout life to illuminate the
role of host-microbial interactions in
immune-mediated diseases. Advances in
epidemiological studies should pave the
way for therapeutic applications of human
SIgA. An obvious starting point would be
to analyze the concentration and activity
of SIgA in donated human milk used to
supplement the diets of newborn infants
faced with challenges such as prematurity
and infectious diseases. For example, the
methods used for pasteurization of donor
milk can dramatically affect its content of
SIgA and other bioactive molecules (for a
review, see ref. 32). SIgA purified from
human colostrum and/or mature milk
could represent a safe, effective and stan-
dardized therapy for infectious, allergic
and inflammatory diseases in infants and
possibly in children and adults. Develop-
ment of SIgA-based therapeutic
approaches should be informed by find-
ings from mechanistic studies regarding
the optimal timing and dosage of SIgA for
specific diseases in targeted populations.
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